Likewise, in the acute phase of IRI, IRF4 acts as an endogenous regulator of myeloid cell activation, i.e., dendritic cells, suppresses TNF-α release from intrarenal myeloid cells, and thereby limits tubular cell necrosis, tissue inflammation, and acute renal failure 24 h and 5 days post-IRI (19). The gene discussed is IRF4; the disease is acute kidney injury.